Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
13 pending office actions • 9 art units • 13 examiners • 0 of 13 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
The University of Southampton is currently managing 13 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 13 distinct examiners and 9 distinct art units, indicating a broad and diverse prosecution landscape for the institution's current filings. The involvement of 13 distinct examiners suggests that the university must manage a wide variety of communication styles.
XING, CHRISTINA ILONA is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. This 1 action is part of the 13 pending office actions spread across the 9 distinct art units involved in the university's current patent office interactions. The workload is highly decentralized, as no single examiner is responsible for more than 1 of the active matters at this time.
The ratio of 13 distinct examiners to 13 pending office actions indicates that every active matter is being reviewed by a different individual. This high level of examiner diversity is paired with a significant reach across 9 distinct art units in the Biotechnology & Pharmaceuticals field. Practitioners should prepare for a wide variety of examination styles and procedural requirements across these 9 distinct art units while maintaining a cohesive overall strategy.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 6 (46%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 2 (15%) |
| Multi-statute (no §101) | 3 (23%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XING, CHRISTINA ILONA | 1 | 82.9% | +17.8% |
| FABIAN JR, ROBERTO | 1 | 71.6% | +27.2% |
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
| GURLEY, JAMI MICHELLE | 1 | 53.3% | +16.1% |
| CHHAY, BONIRATH | 1 | 83.3% | +0.0% |
| ANTISKAY, BRIAN MICHAEL | 1 | 67.2% | +39.3% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.3% |
| CHU, CHRIS H | 1 | 53.2% | +9.4% |
| GEORGE, DENNIS CHERIAN | 1 | 38.5% | +72.7% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837230 | OPTICAL TIME DOMAIN REFLECTOMETRY FOR HOLLOW CORE OPTICAL FIBRES | XING, CHRISTINA ILONA | — |
| 18281530 | NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF | CHHAY, BONIRATH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17440067 | PEPTIDE-INDUCED NK CELL ACTIVATION | DICKINSON, PAUL W | 27d |
| 18564913 | Suppressive T Cell Populations and Methods of Cancer Immunotherapy | GURLEY, JAMI MICHELLE | — |
| 17297102 | METHOD FOR FABRICATING NANOSTRUCTURED OPTICAL ELEMENTS USING POLARISED LIGHT | EVANGELISTA, THEODORE JUSTINE | — |
| 17270403 | METHODS AND COMPOSITONS FOR MODULATIONS OF IMMUNE RESPONSE | SHUPE, ELIZABETH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18651929 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | VAN DRUFF, SYDNEY | 26d overdue |
| 17625226 | Intratumoral TFR Cells Curtail Anti-PD-1 Treatment Efficacy | DENT, ALANA HARRIS | 84d |
| 18837230 | OPTICAL TIME DOMAIN REFLECTOMETRY FOR HOLLOW CORE OPTICAL FIBRES | XING, CHRISTINA ILONA | — |
| 18717742 | MULTI-EXCITATION RAMAN SPECTROSCOPY METHOD AND APPARATUS | FABIAN JR, ROBERTO | — |
| 18564913 | Suppressive T Cell Populations and Methods of Cancer Immunotherapy | GURLEY, JAMI MICHELLE | — |
| 18265580 | REFERENCE ELECTRODE & ION SELECTIVE MEMBRANE | ANTISKAY, BRIAN MICHAEL | — |
| 18037402 | COMPOSITIONS | KATAKAM, SUDHAKAR | — |
| 17627385 | ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS | GEORGE, DENNIS CHERIAN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 2877 | 2 |
| 1645 | 1 |
| 3794 | 1 |
| 1658 | 1 |
| 2874 | 1 |
| 1644 | 1 |
| 1618 | 1 |
| 3700 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837230 | OPTICAL TIME DOMAIN REFLECTOMETRY FOR HOLLOW CORE OPTICAL FIBRES | XING, CHRISTINA ILONA | 2877 | §103 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18717742 | MULTI-EXCITATION RAMAN SPECTROSCOPY METHOD AND APPARATUS | FABIAN JR, ROBERTO | 2877 | §103 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18651929 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | VAN DRUFF, SYDNEY | 1643 | §103 | Non-Final OA | 26d overdue | Pending | May 01, 2024 |
| 18564913 | Suppressive T Cell Populations and Methods of Cancer Immunotherapy | GURLEY, JAMI MICHELLE | — | §101§103§112 | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18281530 | NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF | CHHAY, BONIRATH | 1645 | §103Other | Final Rejection | — | Pending | Sep 11, 2023 |
| 18265580 | REFERENCE ELECTRODE & ION SELECTIVE MEMBRANE | ANTISKAY, BRIAN MICHAEL | 3794 | §103 | Final Rejection | — | Pending | Jun 06, 2023 |
| 18037402 | COMPOSITIONS | KATAKAM, SUDHAKAR | 1658 | §103DP | Final Rejection | — | Pending | May 17, 2023 |
| 18245273 | HOLLOW CORE OPTICAL WAVEGUIDES AND METHODS FOR MODIFICATION THEREOF | CHU, CHRIS H | 2874 | §103 | Final Rejection | 33d | Pending | Mar 14, 2023 |
| 17627385 | ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS | GEORGE, DENNIS CHERIAN | 1644 | §103§112DP | Final Rejection | — | Pending | Jan 14, 2022 |
| 17625226 | Intratumoral TFR Cells Curtail Anti-PD-1 Treatment Efficacy | DENT, ALANA HARRIS | 1643 | DP | Non-Final OA | 84d | Pending | Jan 06, 2022 |
| 17440067 | PEPTIDE-INDUCED NK CELL ACTIVATION | DICKINSON, PAUL W | 1618 | §103§112 | Non-Final OA | 27d | Pending | Sep 16, 2021 |
| 17297102 | METHOD FOR FABRICATING NANOSTRUCTURED OPTICAL ELEMENTS USING POLARISED LIGHT | EVANGELISTA, THEODORE JUSTINE | 3700 | §103§112 | Final Rejection | — | Pending | May 26, 2021 |
| 17270403 | METHODS AND COMPOSITONS FOR MODULATIONS OF IMMUNE RESPONSE | SHUPE, ELIZABETH A | 1643 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial